KalVista Pharmaceuticals (NASDAQ:KALV) Receives Buy Rating from Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report)’s stock price was up 6.8% on Wednesday . The stock traded as high as $12.13 and last traded at $12.12. Approximately 71,232 shares were traded during trading, a decline of 90% from the average daily volume of 700,371 shares. The stock had previously closed at $11.35. Analyst […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par bought 4,174 shares of the business’s stock in a transaction on Friday, January 26th. The stock was purchased at an average cost of $12.98 per share, for a total transaction of $54,178.52. Following the transaction, the insider now owns 4,569,984 shares […]
Prosight Management LP cut its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 61.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 240,000 shares of the specialty pharmaceutical company’s stock after selling 381,667 shares during the quarter. KalVista Pharmaceuticals comprises […]
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) CFO Benjamin L. Palleiko sold 4,037 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $10.14, for a total value of $40,935.18. Following the sale, the chief financial officer now directly owns 78,126 shares in the company, […]